BioSpace News Archive

Earlier this fall, the Company announced a joint working agreement to integrate a major manufacturer’s devices with its HealthTab™ data reporting platform for deployment in Canada, resulting in new testing capabilities, including COVID-19 molecular PCR results via the ID Now™.

REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces its proprietary hypochlorous acid solution has received U.S. Environmental Protection Agency (EPA) approval for a kill claim against SARS-CoV-2, the virus that causes COVID-19

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110.

Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with the U.S. FDA with expected initiation of pivotal Phase 2b/3 trial planned in H2 2021 Conference call today, 14 December, 8:30 AM ET

CCT’s deep experience and industry-leading portfolio of thermal packaging solutions will help to ensure that vaccines with strict refrigeration requirements reach their destinations safely and securely

Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers (“Kalypso”),

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver di

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. Food and Drug Administration (FDA) on Friday, December 11, 2020.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), were presented at the 31st International Symposium on ALS/MND